艾美疫苗(06660)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06660 艾美疫苗

未开盘 08-11 16:08:13

1.635

+0.045

+2.83%

最高1.645	最低1.510	成交量4.30万
今开1.575	昨收1.590	日振幅8.49%
总市值20.05亿	流通市值8.30亿	总股本12.27亿
成交额6.69万	换手率0.01%	流通股本5.08亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06660","market":"HK","secType":"STK","nameCN":"艾美疫苗","latestPrice":1.635,"timestamp":1786435693010,"preClose":1.59,"halted":0,"volume":43000,"delay":0,"changeRate":0.028301886792452786,"floatShares":507673711,"shares":1226562599,"eps":-0.55,"marketStatus":"未开盘","change":0.045,"latestTime":"08-11 16:08:13","open":1.575,"high":1.645,"low":1.51,"amount":66945,"amplitude":0.084906,"askPrice":1.61,"askSize":1200,"bidPrice":1.515,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":-0.614178,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786498200000},"marketStatusCode":0,"adr":0,"listingDate":1664985600000,"exchange":"SEHK","adjPreClose":1.59,"openAndCloseTimeList":[[1786411800000,1786420800000],[1786424400000,1786435200000]],"volumeRatio":0.195526,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06660","defaultTab":"news","newsList":[{"id":"1184422192","title":"艾美疫苗更新2026年7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1184422192","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184422192?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:55","pubTimestamp":1785833755,"startTime":"0","endTime":"0","summary":"2026年8月4日，艾美疫苗股份有限公司（股票代码：06660）发布截至2026年7月31日的证券变动月报。报告显示，本月公司注册股本合计为人民币1,226,562,599元，较上月无增减。\n具体来看，H股已发行股份（不含库存股）数量维持在507,673,711股，内资股已发行股份数量维持在718,888,888股，均无新增发行、购回或注销。公司也未发生库藏股及股份期权、权证、可换股票据等与股本相关的变动。\n截至报告期末，公司股本总数继续保持稳定，艾美疫苗确认已遵守香港联合交易所有限公司《上市规则》及相关法律规定。公告由公司秘书刘灵签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190809189","title":"艾美疫苗(06660)无血清迭代狂犬病疫苗注册进程迈入关键阶段 已向药监部门提交补充资料","url":"https://stock-news.laohu8.com/highlight/detail?id=1190809189","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190809189?lang=zh_cn&edition=full","pubTime":"2026-08-03 08:05","pubTimestamp":1785715532,"startTime":"0","endTime":"0","summary":"2026年8月3日，艾美疫苗股份有限公司发布自愿性公告称，其全资子公司艾美荣誉（宁波）生物制药有限公司已就自主研发的无血清迭代狂犬病疫苗完成上市注册发补资料的提交，标志着该产品注册申报工作取得重要进展。艾美疫苗的新产品在生产过程中不添加任何动物血清组分，可从源头降低不良反应发生概率。\\n\\n艾美疫苗在公告中称，公司目前为全球第二大狂犬病疫苗供应商，将持续推动相关技术升级，并在产品获批后加速商业化投放。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194659193","title":"艾美疫苗6月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1194659193","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194659193?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:15","pubTimestamp":1782983750,"startTime":"0","endTime":"0","summary":"艾美疫苗于2026年7月2日发布截至2026年6月30日的股份变动月报。报告显示，公司注册股本合计1,226,562,599元人民币，包括H股507,673,711股、内资股718,888,888股，面值均为每股人民币1元。上述注册股本数量与上月底保持一致。期权及股权激励计划也无相关增减记录。截至本月末，公司股本总额未发生变动，维持稳定。本次公告由公司秘书刘灵签署。公司表示将持续披露后续股本变动信息。期待进一步加强与投资者的沟通与信息交流。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642442147","title":"艾美疫苗(06660)：吴季南已获委任为执行总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2642442147","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642442147?lang=zh_cn&edition=full","pubTime":"2026-06-10 21:52","pubTimestamp":1781099566,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾美疫苗 发布公告，有关委任刘灵女士(刘女士)为本公司执行董事，以及委任欧阳辉先生和邵伟才先生(邵先生)为本公司独立非执行董事的决议案，已于股东周年大会上获股东正式通过，并自股东周年大会结束时起生效。吴季南先生(吴先生)已获委任为本公司执行总裁、首席科学家兼研发管理委员会主任，并将负责本公司的研发及相关工作。吴先生的任期自2026年6月10日起，并于第二届董事会届满时结束。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452842.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"艾美疫苗(06660)：吴季南已获委任为执行总裁","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120361141","title":"艾美疫苗暂停mRNA人用狂犬疫苗项目并调减PCV13收入预测，整体减少研发开支约2.10亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1120361141","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120361141?lang=zh_cn&edition=full","pubTime":"2026-06-05 22:37","pubTimestamp":1780670260,"startTime":"0","endTime":"0","summary":"艾美疫苗股份有限公司于2026年6月5日就截至2025年12月31日止年度的业绩情况进行了补充披露。公司在综合评估相关mRNA人用狂犬疫苗和mRNA兽用狂犬疫苗的短期研发可行性后，决定暂停推进mRNA人用狂犬疫苗项目，并在减值测试的现金流量预测中相应剔除上述疫苗的收入贡献，使收购产生的递延开发成本估值减少约人民币1.28亿元。另外，受PCV13商业化延迟及相应开发开支加大的影响，公司确认肺炎球菌疫苗相关长期资产减值损失约3.15亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"艾美疫苗暂停mRNA人用狂犬疫苗项目并调减PCV13收入预测，整体减少研发开支约2.10亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124673456","title":"艾美疫苗5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1124673456","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124673456?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:45","pubTimestamp":1780479939,"startTime":"0","endTime":"0","summary":"2026年6月3日，艾美疫苗股份有限公司发布截至2026年5月31日的股份变动月报表。公告显示，公司注册股本合计人民币1,226,562,599元，当期内未发生增发、购回、注销或库藏股等股份变动，股本保持稳定，公共持股量符合香港联交所《上市规则》相关要求。公告同时确认，公司在相关发行及变动中均遵守了监管机构的相关要求和法律法规，并已获得董事会授权。联交所信息显示，艾美疫苗当前公共持股比例符合最低公众持股要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636072799","title":"艾美疫苗(06660)：文洁辞任独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2636072799","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636072799?lang=zh_cn&edition=full","pubTime":"2026-05-18 23:24","pubTimestamp":1779117859,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾美疫苗(06660)发布公告，文洁女士(文女士)因工作安排变动，已辞任独立非执行董事、本公司审计委员会(审计委员会)成员、本公司薪酬与考核委员会成员及本公司提名委员会成员，自新任独立非执行董事于将在2026年6月10日举行的本公司股东周年大会(股东周年大会)上获本公司股东选举起生效。于文女士辞任后，待将于股东周年大会上通过有关增加董事会的董事会成员人数的组织章程细则建议修订的特别决议案后，董事会已议决提名刘灵女士(刘女士)为执行董事，以及提名欧阳辉先生(欧阳先生)及邵伟才先生(邵先生)为本公司独立非执行董事，就此将于股东周年大会上提呈普通决议案供股东审议及批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443175.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06660","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161887124","title":"艾美疫苗拟回购最多10%已发行H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1161887124","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161887124?lang=zh_cn&edition=full","pubTime":"2026-05-18 22:55","pubTimestamp":1779116144,"startTime":"0","endTime":"0","summary":"艾美疫苗股份有限公司公告称，其董事会已决议建议向股东大会申请一般性授权，以回购不超过于股东大会批准当日已发行且尚未回购H股总数10%的股份。根据公告，董事会认为适度回购股权将有助于改善每股资产净值和每股收益水平，并认为此举符合公司及股东的最佳利益。公司H股股份过户登记将于2026年6月5日至6月10日期间暂停办理，股权登记日为6月10日。完成回购的H股将同时注销，公司注册资本相应调减。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"艾美疫苗拟回购最多10%已发行H股","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635943788","title":"格隆汇个股放量排行榜 | 5月13日","url":"https://stock-news.laohu8.com/highlight/detail?id=2635943788","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635943788?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:30","pubTimestamp":1778664605,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日腾讯音乐-SW(01698)、阳光保险(06963)、上海电气(02727)、轻松健康(02661)、弘毅文化集团(00419)、FIT HON TENG(06088)、京城机电股份(00187)、北方矿业(00433)、心玮医疗-B(06609)、同源康医药-B(02410)、富通科技(00465)、京东物流(02618)、云顶新耀(01952)、赛晶科技(005","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/13173057083788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01024","06969","09888","06963","09992","06996","00772","09626","00909","02126","06609","02276","02618","02096","06160","01952","00719","00013","02285","02171","02306","02197","00136","00169","00762","01783","02013","01951","02252","02158","01548","01060","02192","02256","06660","09699","01357","03692","09858","01440","81024","06049","01905","06060","06186","01833","03700","03888","09688","02172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186576469","title":"艾美疫苗4月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1186576469","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186576469?lang=zh_cn&edition=full","pubTime":"2026-05-06 17:00","pubTimestamp":1778058056,"startTime":"0","endTime":"0","summary":"艾美疫苗股份有限公司于2026年5月6日发布2026年4月的股份变动月报表，报告期为2026年4月1日至2026年4月30日。公告显示，该公司已发行及注册股本在本月并无新增发行、购回或注销活动，股本维持不变。根据公告，艾美疫苗股份有限公司将继续确保公司股票拥有足够的公众持股量，其股本情况在报告期内维持稳定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130442746","title":"艾美疫苗2025年营收下滑、亏损加剧，聚焦无血清狂苗与mRNA多管线研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1130442746","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130442746?lang=zh_cn&edition=full","pubTime":"2026-04-27 16:56","pubTimestamp":1777280210,"startTime":"0","endTime":"0","summary":"公司管理层在年报中指出，核心业务围绕疫苗研发与创新技术迭代，重点推进无血清狂苗及mRNA疫苗等多条管线研发。企业将深度利用AI科技加速疫苗研制与国际市场布局，并提出“决胜2026”三大创新发展方向：加快无血清狂苗上市进度、打造大单品研发管线以及推动多款疫苗出海开拓国际市场。整体而言，在2025年度，公司面临营收与盈利能力下滑、资产减值等压力，同时也积极投入疫苗技术攻关，持续推进无血清狂苗等在研产品的落地。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"艾美疫苗2025年营收下滑、亏损加剧，聚焦无血清狂苗与mRNA多管线研发","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627440658","title":"港股异动 | 艾美疫苗(06660)现涨超5% 公司拟申请在北交所上市 全球首款无血清狂苗上市在即","url":"https://stock-news.laohu8.com/highlight/detail?id=2627440658","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2627440658?lang=zh_cn&edition=full","pubTime":"2026-04-15 14:53","pubTimestamp":1776236029,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，艾美疫苗现涨超5%，截至发稿，涨5.17%，报3.05港元，成交额940.29万港元。消息面上，3月30日，艾美疫苗董事会审议通过：拟增发不超过4000万股内资股，不超过本次发行前公司已发行股份总数的约3.2611%，并计划推动内资股在全国股转系统挂牌，进一步申请在北京证券交易所上市。公开资料显示，艾美疫苗共20款在研疫苗，拥有24个临床批件，公司正在稳步推动产品线布局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428730.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","06660","BK4588","BK4585","VXUS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134557893","title":"艾美疫苗2026年3月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1134557893","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134557893?lang=zh_cn&edition=full","pubTime":"2026-04-02 16:42","pubTimestamp":1775119342,"startTime":"0","endTime":"0","summary":"艾美疫苗股份有限公司（股票代码：06660）于2026年4月2日发布2026年3月股份变动月报表，报告期为2026年3月1日至3月31日。公告显示，公司本月无新增股份发行或回购注销行为，整体股本结构保持不变。\n艾美疫苗股份有限公司目前注册股本为1,226,562,599股，其中包括507,673,711股H股及718,888,888股内资股。截至报告期末，H股与内资股数量与上月一致，均未发生数量变动。此外，公司报告期内未发生任何购回或库存股份变动，也无期权或股权激励计划的进展信息。\n公告称，公司已遵守香港联合交易所有限公司上市规则及相关法律规定。该月报由公司秘书刘灵签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624216445","title":"港股异动 | 艾美疫苗(06660)盘中涨近8% 拟向北交所申请A股上市 “H+A”战略有望带动估值提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2624216445","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2624216445?lang=zh_cn&edition=full","pubTime":"2026-04-02 10:52","pubTimestamp":1775098341,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，艾美疫苗盘中涨近8%，截至发稿，涨6.78%，报3.15港元，成交额237.95万港元。并且，公司拟向北京证券交易所申请A股上市。根据北京证券交易所A股上市相关规定，公司的内资股股份需于全国中小企业股份转让系统申请挂牌。艾美疫苗若实现“H+A”的战略布局，不仅有利于提升公司港股估值及二级市场活跃度，其品牌价值和业务也将得到飞速发展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424416.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","VXUS","159982","399300","06660","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623732701","title":"艾美疫苗(06660)拟向北交所申请A股上市 有望成“H+北”第一股","url":"https://stock-news.laohu8.com/highlight/detail?id=2623732701","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2623732701?lang=zh_cn&edition=full","pubTime":"2026-03-31 07:30","pubTimestamp":1774913436,"startTime":"0","endTime":"0","summary":"并且，公司拟向北京证券交易所申请A股上市。根据北京证券交易所A股上市相关规定，公司的内资股股份需于全国中小企业股份转让系统申请挂牌。艾美此次进程若顺利落地，有望成为从港股回北交所上市的第一家企业，开创港股生物医药公司赴北交所上市的先河。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06660","159982","399300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617081568","title":"每日卖空追踪 | 艾美疫苗 03月04日卖空量成交2200股，卖空比例为0.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617081568","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2617081568?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:30","pubTimestamp":1772613037,"startTime":"0","endTime":"0","summary":"艾美疫苗北京时间03月04日，跌1.34%，卖空量成交2200股，较上一交易日减少91.85%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。港股数据实时性强，适合短线跟踪；美股因T+2延迟，更适用中长期分析。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163548a44a7061&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163548a44a7061&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06660","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616585039","title":"艾美疫苗03月03日主力净流出154.5万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2616585039","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2616585039?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:15","pubTimestamp":1772525748,"startTime":"0","endTime":"0","summary":"03月03日, 艾美疫苗股价跌5.40%，报收2.98元，成交金额443.5万元，换手率0.29%，振幅8.25%，量比3.27。艾美疫苗今日主力资金净流出154.5万元，上一交易日主力净流入31.5万元。该股近5个交易日下跌9.42%，主力资金累计净流出123.0万元；近20日主力资金累计净流出376.6万元，其中净流出天数为4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303161925a69c99cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303161925a69c99cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06660","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609155372","title":"艾美疫苗(06660)全球自主首研的无血清迭代狂犬疫苗顺利通过注册现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2609155372","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2609155372?lang=zh_cn&edition=full","pubTime":"2026-02-05 20:05","pubTimestamp":1770293107,"startTime":"0","endTime":"0","summary":"截至目前，艾美荣誉已顺利通过药物临床试验现场检查及药品注册生产现场检查。此前，艾美荣誉已取得无血清迭代狂犬疫苗相应的产品生产许可证。目前，全球市场上尚未有无血清狂犬疫苗获批上市，该集团该产品上市后，将有望弥补市场空白。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402225.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159646","06660","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518758410","title":"艾美疫苗盘中异动 股价大跌5.12%报3.890港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518758410","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518758410?lang=zh_cn&edition=full","pubTime":"2025-03-11 10:31","pubTimestamp":1741660302,"startTime":"0","endTime":"0","summary":"2025年03月11日早盘10时31分，艾美疫苗股票出现波动，股价急速下挫5.12%。艾美疫苗股票所在的药品行业中，整体涨幅为0.12%。值得注意，艾美疫苗当前业绩并不理想，自2021年起，公司营收增速放缓，业绩出现大幅亏损。目前，艾美疫苗的收入主要来源于其核心产品乙肝疫苗和狂犬病疫苗，其中狂犬病疫苗收入占比近六成。另外，复星国际证券在研报中指出，艾美疫苗的13价肺炎疫苗和23价肺炎疫苗预计分别为2025年和2026年获批。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031110314398a341a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031110314398a341a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06660","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518509152","title":"艾美疫苗三年亏损超23亿，高端疫苗如何突围？","url":"https://stock-news.laohu8.com/highlight/detail?id=2518509152","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518509152?lang=zh_cn&edition=full","pubTime":"2025-03-10 10:51","pubTimestamp":1741575102,"startTime":"0","endTime":"0","summary":"三年间，公司累计亏损超23亿元。目前，艾美疫苗的收入主要来源于其核心产品乙肝疫苗和狂犬病疫苗，其中狂犬病疫苗收入占比近六成。证券之星梳理发现，艾美疫苗近年收入下滑的主因之一是其核心产品狂犬病疫苗的收入失速。从短期来看，这些被艾美疫苗寄予厚望的狂犬疫苗产品无法做出收入贡献。另外，复星国际证券在研报中指出，艾美疫苗的13价肺炎疫苗和23价肺炎疫苗预计分别为2025年和2026年获批。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310105152963f9532&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310105152963f9532&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06660","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aimbio.com","stockEarnings":[{"period":"1week","weight":-0.021},{"period":"1month","weight":0.09},{"period":"3month","weight":-0.3944},{"period":"6month","weight":-0.4674},{"period":"1year","weight":-0.6737},{"period":"ytd","weight":-0.4907}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":0.0611},{"period":"3month","weight":-0.0279},{"period":"6month","weight":-0.051},{"period":"1year","weight":0.03},{"period":"ytd","weight":0.0009}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"艾美疫苗股份有限公司是一家主要从事疫苗研发、制造和销售的中国公司。该公司的产品主要包括重组乙型肝炎疫苗、人用狂犬病疫苗、甲型肝炎灭活疫苗、腮腺炎疫苗、肾综合征出血热灭活疫苗和MPSV4。该公司的产品主要用于治疗乙肝、甲肝、腮腺炎、肾综合征出血热、狂犬病和脑膜炎球菌病。该公司的在研疫苗包括信使核糖核酸（mRNA）新冠（COVID-19）疫苗、灭活新冠疫苗、广谱新冠疫苗、PCV13、PPSV23及MCV4。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.052664},{"month":2,"riseRate":0.5,"avgChangeRate":0.02733},{"month":3,"riseRate":0.5,"avgChangeRate":0.138475},{"month":4,"riseRate":0.25,"avgChangeRate":-0.094553},{"month":5,"riseRate":0.5,"avgChangeRate":0.029763},{"month":6,"riseRate":0.25,"avgChangeRate":-0.09386},{"month":7,"riseRate":0.5,"avgChangeRate":0.035575},{"month":8,"riseRate":0.75,"avgChangeRate":-0.030277},{"month":9,"riseRate":0.333333,"avgChangeRate":0.144896},{"month":10,"riseRate":0,"avgChangeRate":-0.306447},{"month":11,"riseRate":0,"avgChangeRate":-0.121084},{"month":12,"riseRate":0.25,"avgChangeRate":-0.055586}],"exchange":"SEHK","name":"艾美疫苗","nameEN":"AIM VACCINE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾美疫苗(06660)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾美疫苗(06660)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾美疫苗,06660,艾美疫苗股票,艾美疫苗股票老虎,艾美疫苗股票老虎国际,艾美疫苗行情,艾美疫苗股票行情,艾美疫苗股价,艾美疫苗股市,艾美疫苗股票价格,艾美疫苗股票交易,艾美疫苗股票购买,艾美疫苗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾美疫苗(06660)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾美疫苗(06660)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}